HIV/AIDS communities and AIDS vaccine research
description
Transcript of HIV/AIDS communities and AIDS vaccine research
HIV/AIDS communities and AIDS vaccine research
AIDES / TRT-5Tour Essor14, rue Scandicci93508 Pantin Cedex
Questions from the community ANRS and vaccine trials of therapeutic
vaccines ANRS and recruitment of HIV-
volunteers to participate to vaccine trials (safety issues raised)
Partnership with African NGOs (Réseau Afrique 2000): how far are we from a vaccine?
To stop the spread of AIDS
To be better informed
TRT-5 first met with the ANRS investigators (1999) Aventis (Alvac) in 1999
Attendance to scientific meetings
Internal training sessions (immunologists)
To inform(articles in our newsletters)
To inform(training sessions in Africa)
To inform(symposium on immunology)
To inform
Press releases after the announcement of the results of the ANRS trials
Press release after AIDSVAX results
To link up
Vaccine Working Group
IAVI partnership
Microbicides initiative
To work with ANRS
AC5 Clinical trials: to have two community representatives (voting rights)
AC28 Preventive vaccines: two community representatives (one from the HIV community and one from the volunteers) Modification of design of clinical trials Set up of the long term follow up of
vaccinees
To lobby
Towards the Industry to have access to vaccine preparation (Aventis supplied Orvéac with ALVAC after a TRT-5 meeting)
Authorities to maintain a strong commitment to prolong the ANRS
Within the ANRS, AC28 to finally do a proper work!
To lobby
Within our organization for preventive technologies to be a priority
EU for commitment French government to pursue funding
for a preventive vaccine. Does it have to be only directed to the ANRS?